source
- BMS faces steep risk if milvexian trial fails, could spark mega-cap merger frenzyBMS is heading toward a readout for its oral FXIa inhibitor milvexian, a trial that analysts say could be pivotal for the company's future growth. The recent collapse of merger talks with AstraZen…
- FDA to tighten oversight of foreign clinical trial sites as China trial volume soarsFDA officials wrote an editorial stating that inspection access is not an administrative footnote and announced plans to expand oversight of foreign clinical trial sites. The initiative follows th…